|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-8-28
|
|
pubmed:abstractText |
The use of immunosuppressive therapies after solid organ transplantation has been shown to increase a patient's risk for Epstein-Barr virus (EBV)-associated lymphoma. A potential therapy for this disorder is the adoptive transfer of EBV-specific cytotoxic T lymphocytes (CTLs). We proposed that dendritic cells (DCs) could be loaded with EBV antigens and be used to improve the in vitro generation of EBV-specific CTLs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0039-6060
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
124
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
171-6
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9706135-Antigens, Viral,
pubmed-meshheading:9706135-B-Lymphocytes,
pubmed-meshheading:9706135-Chromium Radioisotopes,
pubmed-meshheading:9706135-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:9706135-Dendritic Cells,
pubmed-meshheading:9706135-Flow Cytometry,
pubmed-meshheading:9706135-Herpesvirus 4, Human,
pubmed-meshheading:9706135-Humans,
pubmed-meshheading:9706135-Immunophenotyping,
pubmed-meshheading:9706135-Immunosuppressive Agents,
pubmed-meshheading:9706135-Lymphocyte Activation,
pubmed-meshheading:9706135-Lymphoma,
pubmed-meshheading:9706135-Organ Transplantation,
pubmed-meshheading:9706135-Postoperative Complications,
pubmed-meshheading:9706135-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
|
|
pubmed:affiliation |
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
|
|
pubmed:publicationType |
Journal Article
|
